Biobizoo Co., Ltd., a medical aesthetics company and subsidiary of Cheongdam Global, announced on the 16th that it had passed the preliminary screening for KOSDAQ listing by the Korea Exchange.
Biobiz plans to file a securities report and begin a full-scale public offering schedule, and Daishin Securities has been appointed as the lead manager for the listing.
Founded in 2018, Biovisu is a medical aesthetics company that develops, manufactures, and sells differentiated technologies and customized materials and products. From the beginning, it has aimed to enter overseas markets. Currently, it is expanding its network in 21 countries including China, Southeast Asia, Europe, CIS, the Middle East, and South America. Its main products include skin boosters, fillers, and cosmetics, and they are produced and sold based on GMP manufacturing facilities.
Biobiz recorded sales of KRW 17.1 billion in 2023, and achieved cumulative sales of KRW 20.3 billion and operating profit of KRW 6 billion in the third quarter of 2024. This is a performance that exceeded the annual performance of 2023 in just three quarters.
In addition, Biobijoux announced that CDL (Kandorup) cosmetics, which were launched in December of last year, recorded sales of over 4 billion won on TikTok and Xiaohongshu platforms in the Chinese market. The company said that explosive sales growth is expected this year along with the increase in sales of existing products. In the future, the company plans to focus on developing products such as 'tissue repair biomaterials', 'cosmetic medical devices', and 'inner beauty' using new materials, and to further strengthen market competitiveness through new technology research.
You must be logged in to post a comment.